Table 4 Relative Risk of Mortality in Patients with De Novo Metastatic Breast Cancer by Period of Diagnosis.

From: Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting

Death

Period of diagnosis

1996–2000a

2001–2005

2006–2010

Relative excess risk (95% CI)b

1.0

0.86 (0.68–1.09)

0.68 (0.54–0.86)h

Relative excess risk (95% CI)c

1.0

0.82 (0.65–1.05)

0.68 (0.54–0.87)h

Relative excess risk (95% CI)d

1.0

0.82 (0.64–1.05)

0.66 (0.52–0.84)h

Relative excess risk (95% CI)e

1.0

0.82 (0.64–1.05)

0.71 (0.56–0.89)h

Relative excess risk (95% CI)f

1.0

0.87 (0.68–1.12)

0.77 (0.61–0.98)h

Relative excess risk (95% CI)g

1.0

0.89 (0.69–1.16)

0.79 (0.62–1.01)

  1. aReference period.
  2. bDerived using Poisson regression model, adjusted for center and follow-up time.
  3. cSimilar as model 2 and additionally adjusted for age at diagnosis and ethnicity.
  4. dSimilar as model 3 and additionally adjusted for T stage at diagnosis, ER status, number of organs with metastatic involvement and presence of visceral metastasis.
  5. eSimilar as model 4 and additionally adjusted for systemic therapy (chemotherapy and hormone therapy).
  6. fSimilar as model 5 and additionally adjusted for surgery of primary tumor, surgical margins.
  7. gSimilar as model 6 and additionally adjusted for radiotherapy of breast, chest wall and other metastatic sites.
  8. hStatistically significant.
Back to article page